The BD Max test uses a single nasal swab or nasopharyngeal swab sample to determine if a patient has COVID-19, the flu or RSV. Franklin Lakes, N.J.-based BD designed the test to eliminate the need for multiple tests or doctor visits and to increase testing capacity during flu season.
“SARS-Cov-2, influenza and RSV are a triple threat, as patient symptoms and clinical presentation can be nearly identical,” said Nikos Pavlidis, VP of molecular diagnostics at BD. “A combined testing panel is key to enabling clinicians to quickly and efficiently diagnose, differentiate and treat patients to help manage the spread of the infections.”
BD Max system is already in use at thousands of laboratories worldwide and is capable of analyzing hundreds of samples over a 24-hour period. The RVP assay is an RT-PCR assay that detects and differentiates the mRNA of SARS-CoV-2, flu A, flu B and RSV in two hours using the Max system.
BD Max RVP is available in countries that recognize CE mark. The company plans to submit for emergency use authorization in the U.S. in the coming weeks.
